This section contains press releases and other materials from third parties (including paid content). JOBFlocks has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Eli Lilly & Co (LLY) and Liquidia Technologies (LQDA)

Tipranks - Tipranks - Fri Oct 2, 10:52AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zoetis (ZTS), Eli Lilly & Co (LLY) and Liquidia Technologies (LQDA).

Zoetis (ZTS)

Leerink Partners analyst Daniel Clark reiterated a Hold rating on Zoetis today. The company’s shares closed last Thursday at $70.19.

According to TipRanks.com, Clark is a 3-star analyst with an average return of 9.9% and a 58.3% success rate. Clark covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Collegium Pharmaceutical, and Phathom Pharmaceuticals. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zoetis with a $91.25 average price target, which is a 30.4% upside from current levels. In a report issued on September 18, Stifel Nicolaus also reiterated a Hold rating on the stock.

See the top stocks recommended by analysts >>

Eli Lilly & Co (LLY)

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Eli Lilly & Co today. The company’s shares closed last Thursday at $1149.70.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 27.4% and a 59.0% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Protagonist Therapeutics, and Madrigal Pharmaceuticals. ;'>

Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $1364.15, which is a 18.1% upside from current levels. In a report issued on September 21, Barclays also maintained a Buy rating on the stock with a $1400.00 price target.

Liquidia Technologies (LQDA)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Hold rating on Liquidia Technologies. The company’s shares closed last Thursday at $25.50.

According to TipRanks.com, Gerberry is a 5-star analyst with an average return of 19.6% and a 60.3% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Mineralys Therapeutics, Inc., and Amylyx Pharmaceuticals Inc. ;'>

Currently, the analyst consensus on Liquidia Technologies is a Moderate Buy with an average price target of $81.20, representing a 238.9% upside. In a report released today, TipRanks – Google also downgraded the stock to Hold with a $76.00 price target.

Read More on ZTS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Market data provided by Barchart. Exchange delay details and data provider terms here. Information may be delayed, is provided 'as is' and is solely for informational purposes, and not for trading, investment or advice.